Enliven Therapeutics Stock (NASDAQ: ELVN)

Enliven Therapeutics

Enliven Therapeutics Inc is a clinical-stage precision oncology company focused on the discovery and development of potentially first-in-class precision oncology therapies. Enliven's programs are designed to address issues such as tolerability, combinability, resistance and disease escape through brain metastases. Its product candidates include ELVN-001 which is a potent, selective, small molecule kinase inhibitor designed to specifically target the BCR-ABL gene fusion, the oncogenic driver for patients with chronic myeloid leukemia, and the ELVN-002 which is central nervous system (CNS) penetrant and irreversible HER2 inhibitor with activity against wild type HER2 and various HER2 mutations.

Wall Street

News

Initiation

Markets

Analyst Ratings

Trading Ideas

ALMS

BRZE

ELVN

INTS

TERN

This Alumis Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

Biotech

Earnings

Small Cap

General

Most of us have heard the dictum &#34;the trend is your friend.&#34; And this is undeniably the key to success when it comes to short-term investing or trading. But it isn&#39;t easy to ensure the sustainability of a trend and profit from it.

Enliven Therapeutics, Inc. Is a Great Choice for &#39;Trend&#39; Investors, Here&#39;s Why

Health Care

Movers

RHHBY

HC Wainwright initiated coverage on Enliven Therapeutics, noting its innovative small molecules for tumor treatments. HC Wainwright gave a Buy rating with a $37 price target, projecting significant sales potential for Enliven&#39;s therapies.

Enliven Therapeutics&#39; Leukemia Candidate Could Challenge Pfizer, AstraZeneca In Broader Target Market: Analyst

Enliven Therapeutics, Inc. - Common Stock

Enliven Therapeutics Inc

Press Releases

Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update

Enliven Therapeutics to Present at Two Upcoming Investor Conferences

Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update

Enliven Therapeutics Announces Details Regarding the Presentation of Updated ELVN-001 Phase 1a Data at the ESH-iCMLf 26th Annual John Goldman Conference on CML

Enliven Therapeutics Announces Positive Data Update from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia

Opinion

FDA Approves 16 New Cancer Treatments as Global Cancer Rates Skyrocket

Enliven Therapeutics to Present at the Jefferies London Healthcare Conference

Enliven Therapeutics Reports Third Quarter Financial Results and Provides a Business Update

Clear Street Launches Healthcare & Biotechnology Equity Research

Enliven Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference

ABBV

BGNE

CGEM

CRGX

DCTH

ERAS

IMTX

IPSC

JANX

MLTX

NUVB

ONCY

PTGX

TSX:ONC

YMAB

Amphastar Pharmaceuticals, Inc. - Common Stock

Amphastar Pharma

ANI Pharmaceuticals

Arvinas

BGM Group

Collegium Pharmaceutical, Inc. - Common Stock

Collegium Pharmaceutical

Cormedix

Evolus

EyePoint Pharmaceuticals, Inc. - Common Stock

EyePoint Pharmaceuticals

GH Research

Structure Therapeutics Inc. - American Depositary Shares

Structure Therapeutics

Harrow

Indivior

Innoviva

Liquidia

Maze Therapeutics

Nuvation Bio

Ocular Therapeutix

Omeros

Phibro Animal Health Corporation - Class A Common Stock

Phibro Animal Health

Pacira BioSciences

Tarsus Pharmaceuticals, Inc. - Common Stock

Tarsus Pharmaceuticals

Theravance Biopharma, Inc. - Ordinary Shares

Theravance Biopharma

Tilray Brands

Wave Life Sciences Ltd. - Ordinary Shares

WAVE Life Sciences

Xeris Biopharma Holdings, Inc. - Common Stock

Xeris Biopharma Holdings

BTIG

Baird

Jones Trading

HC Wainwright & Co.

Mizuho

Comments

Enliven Therapeutics

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga